SPC515
Lazertíníb á öllum formum þess sem eru vernduð af grunneinkaleyfinu / Lazertinib in all its forms protected by the basic patent
:
Umsókn:
2.6.2025:
1.7.2025
:
Lazcluze
2.6.2025
1.7.2025
:
EU/1/24/1886:
20.1.2025
:
Yuhan Corporation:
74 Noryangjin-ro Dongjak-gu, Seoul KR
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113 Reykjavík